Please login to the form below

Not currently logged in
Email:
Password:

Boehringer returns to growth in first half

German firm back on track after a tough sales period

BI HQ  

Boehringer Ingelheim has started to see the glimmerings of a recovery after a difficult couple of years thanks to solid growth in its diabetes franchise.

The first half of 2015 saw currency-adjusted group sales rise by around 2% to €7.4bn - reversing declines that extended through 2013 and 2014 - while its pharma division managed a 1% increase to reach €5.4bn thanks to higher sales of its Trajenta (linagliptin) franchise. The flattering effect of the weak euro meant reported group sales rose 13%.

Trajenta and combination product Jentadueto (linagliptin and metformin) climbed 22% to €419m in the six-month period, although this growth rate is well below the same period of 2014 when it was climbing more than 60% and likely reflect increased competition in the diabetes market.

DPP-4 inhibitor Trajenta competes head-to-head with a number of other drugs in the class, including Novo Nordisk's which also grew 22% to reach 8.4bn Danish krone (€1.1bn) in the first half of the year.

Boehringer's chairman Andreas Barner said the company - alongside its peers in the industry - continues to face challenges "as a result of the fast-changing US market and the tougher competition from generics in Japan."

The company is in the throes of a restructuring exercise to boost its profitability and last month announced the sale of its US generics unit to Jordan's Hikma for $2.6bn, having previously sold its injectable generic firm Bedford Labs to the same company for $300m.

The company is looking to its pipeline to accelerate growth, and chalked up a number of recent successes including the marketing application for idarucizumab, a reversal agent for its anticoagulant Pradaxa (dabigatran), and the approval of lung cancer therapy Giotrif (afatinib).

Meanwhile, its diabetes franchise - which Barner said would be "one of the main growth drivers in this business in the years to come" - has been bolstered by EU approval for Synjardy (empagliflozin and metformin) and US approval for Glyxambi (empagliflozin and linagliptin).

The company's top-selling drug Spiriva (tiotropium) for chronic obstructive pulmonary disease (COPD) achieved sales of €1.76bn - up from €1.62bn in the same period of 2014 - and was recently joined on the market by combination follow-up Spiolto (tiotropium and olodaterol).

Privately-owned Boehringer did not give any details about sales of Pradaxa, however, which is facing strong competition in the novel oral anticoagulant (NOAC) market from Pfizer's Eliquis (apixaban) and Bayer/Johnson & Johnson's Xarelto (rivaroxaban), as well as Daiichi Sankyo's new entrant Lixiana/Savaysa (edoxaban).

Article by
Phil Taylor

6th August 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics